Skip to main content
SpringerPlus
Fig. 3 | SpringerPlus

Fig. 3

From: Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study

Fig. 3

Eligibility and responses for HD-MTX. a Age distribution of patients and eligibility for HD-MTX. For initial HD-MTX therapy, 85.2 % patients were eligible (white), and nine were unfit for treatment (black). b In total, 57.7 % patients achieved a complete response (light gray), and 22 other responses (dark gray) for initial HD-MTX. c Kaplan–Meier estimate of overall survival by eligibility for initial HD-MTX. Median survival for patients eligible for treatment was 54.1 months (95 % CI 30.7–100.1 months) compared with 13.3 months (95 % CI 1.2–27.5 months) for those not eligible (Log rank p < 0.0001). d Kaplan–Meier estimate of overall survival by the response to the initial HT-MTX. Median survival for patients with complete response was 100.1 months (95 % CI 55.4 months to upper limit not available), compared with those with other responses 15.2 months (95 % CI 4.5–41.6 months (Log rank p < 0.0001). HD-MTX high-dose methotrexate, CR complete response, PR partial response, PD progressive disease, OS overall survival

Back to article page